http://www.raredr.com/conferences/nla2015/clinical-trials-isis-apociiirx
Clinical Trials with Volanensorsen (ISIS-APOCIIIrx): Familial Chylomicronemia Syndrome and Partial Lypodystrophy

James Radke, PhD




Paula Soteropoulos, president and chief executive officer of Akcea Therapeutics, a subsidiary of Isis Pharmaceuticals focused on delivering transformative medicines for cardiometabolic lipid disorders, talks about the phase 3 clinical studies the company is conducting to bring volanesorsen (ISIS-APOCIIIRX) to market. 

To learn more about the clinical trials, go to www.apociii.com
 
Printer Printing...
$content$